A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol

In this video, Shane Karnik, Sr. Laboratory Director for Aliri Bioanalysis, offers a quick overview of a scientific poster about a derivatization-free LCMS assay for 4β-hydroxycholesterol presented at the 2024 AAPS conference.

4β-Hydroxycholesterol is an important biomarker for assessing the activity of CYP3A in clinical studies. Numerous quantitative methods have been reported for analyzing the total amount of 4β-hydroxycholesterol (free and conjugated) after saponification and derivatization. Derivatization is often required to achieve clinically relevant assay sensitivity when utilizing LCMS for detection, but this additional step can be complex and time-consuming.

This new method eliminates the need for derivatization, which can save time and money. It is also more sensitive than traditional methods, meaning it can be used to measure 4β-hydroxycholesterol levels in smaller samples.

Watch the video to learn more about this exciting new development!